ライフサイエンスコーパス: overdose

1 der the mental health act; and one attempted overdose).

2 ia) and their adverse effects (addiction and overdose).

3 5 mg Fe/g liver phantom iron overload (100X overdose).

4 mortality risk, especially for drug-related overdose.

5 ostic biomarker of patient outcome post-APAP overdose.

6 ating miRNome in patients with acetaminophen overdose.

7 h heroin, and can result in lethality during overdose.

8 han serum creatinine concentration post-APAP overdose.

9 ign of next-generation therapeutics for drug overdose.

10 ed in improved liver regeneration after APAP overdose.

11 reversal of cardiac toxicity caused by drug overdose.

12 HPC transplantation and acetaminophen (APAP) overdose.

13 considerable risk factor for death in heroin overdose.

14 52) in patients presenting within 8 hours of overdose.

15 ng MOR signaling during addiction and opioid overdose.

16 ns prior to inducing asystole by bupivacaine overdose.

17 h life-threatening liver disease due to APAP overdose.

18 nce use diagnoses with death from accidental overdose.

19 s to describe acute liver injury due to APAP overdose.

20 nd may present a novel therapy to treat APAP overdose.

21 improves hepatocyte regeneration after APAP overdose.

22 of serum indicated a definite acetaminophen overdose.

23 pposed progression of liver injury upon APAP overdose.

24 erase activity seen in humans following APAP overdose.

25 companied by an epidemic of opioid abuse and overdose.

26 t can cause severe hepatotoxicity if used at overdose.

27 and QTc intervals, as seen with azithromycin overdose.

28 orphine equivalents) received at the time of overdose.

29 her risk of subsequent opioid dependency and overdose.

30 istered intravenously to treat acetaminophen overdose.

31 , motor activation, self-administration, and overdose.

32 ievement of CNA and to prevent toxicity from overdose.

33 d prompter emergency intervention in case of overdose.

34 in the liver of patients with acetaminophen overdose.

35 ffective medication for treatment of cocaine overdose.

36 e is associated with lower risk for repeated overdose.

37 ous risks, including opioid use disorder and overdose.

38 e treated for a nonfatal prescription-opioid overdose.

39 d treatment for nonfatal prescription-opioid overdose.

40 of patients (n = 212) had a repeated opioid overdose.

41 ays before to up to 730 days after the index overdose.

42 nue to receive prescription opioids after an overdose.

43 mon drugs associated with unintentional drug overdose.

44 s were dispensed to 91% of patients after an overdose.

45 e drugs and changing the geography of opiate overdoses.

46 tributor to the rising mortality from opioid overdoses.

47 ave been reported from single-agent hypnotic overdoses.

48 ritically ill to both piperacillin under and overdosing.

49 ommon self-harm mechanism was an intentional overdose (115 [72.8%]).

50 -of-hospital deaths other than unintentional overdose (120 long-acting opioid, 53 control deaths), th

51 ving high dosages of opioids after the index overdose, 15% (CI, 10% to 21%) for those receiving moder

52 ed patients (9.4%) were underdosed, 197 were overdosed (3.4%), and 5,000 were dosed according to U.S.

53 not receive Lipid Emulsion after bupivacaine overdose (330+/-42 nmol/mg vs. 180+/-8.2 nmol/mg of mito

54 The leading causes of death were overdose (57.9%), self-inflicted injury (13.2%), trauma/

55 f hospitalizations were due to unintentional overdoses (65.7%; 95% CI, 60.1 to 71.3).

56 nduced in vivo in the liver by acetaminophen overdose, a condition causing severe oxidative mitochond

57 injury pattern associated with acetaminophen overdose: a predominance of female gender, very high ami

58 have been accompanied by increases in opioid overdoses, abuse, and other harms and uncertainty about

59 Seizures and overdoses accounted for 25 of the 29 related SAEs.

60 ratio, 2.85; 95% CI, 1.54-5.47), and opioid overdose (adjusted hazard ratio, 5.12; 95% CI, 1.63-19.6

61 s in potentially hazardous use of opioids or overdose among disabled Medicare beneficiaries, a popula

62 Innovation is needed to reduce the risk for overdose among former prisoners.

63 In response to reports of unintentional drug overdoses among children given over-the-counter (OTC) li

64 (INR) measurements on admission to estimate overdose amount, time elapsed since overdose, and outcom

65 MALD provides a method to estimate overdose amount, time elapsed since overdose, and outcom

66 nown therapeutic exposures and acetaminophen overdoses, an adduct concentration >/=1.0 nmol/mL of ser

67 omising for therapeutic treatment of cocaine overdose and addiction as an exogenous enzyme in human.

68 s a promising treatment strategy for cocaine overdose and addiction, because CocE is the most efficie

69 ractive potential treatment for both cocaine overdose and cocaine addiction.

70 We excluded studies of deliberate overdose and depression in non-ICU settings.

71 trate liver as early as 8-12 hours post-APAP overdose and form dense cellular clusters around necroti

72 ng pathways in liver regeneration after APAP overdose and highlighted canonical Wnt signaling as a po

73 ole of GSK3 in liver regeneration after APAP overdose and identified GSK3 as a potential therapeutic

74 n the cognitive therapy group (one attempted overdose and one patient presenting risk to others, both

75 could in turn reduce the risk of death from overdose and risk behaviours.

76 in cases of acute liver failure due to APAP overdose and should be validated in multicenter prospect

77 an APAP overdose depends on the size of the overdose and the time to first administration of N-Ac.

78 pants in the BA group (two [1%] patients who overdosed and one [1%] who self-harmed) and eight (4%) p

79 articipants in the CBT group (seven [4%] who overdosed and one [1%] who self-harmed).

80 ilistic analyses and incorporating recurrent overdoses and a secondary analysis assuming heroin users

81 se was associated with less frequent heparin overdosing and modestly greater adherence to acute MI gu

82 be multifactorial, including a dopaminergic 'overdose' and structural changes in the frontostriatal c

83 nal indication for dose reduction (potential overdosing) and use of a reduced dose when the renal ind

84 ed public health issues of opioid diversion, overdose, and addiction.

85 reased risks, including opioid use disorder, overdose, and death, with dose-dependent effects.

86 n Scotland), were diagnosed with paracetamol overdose, and gave written informed consent.

87 ignificantly older, less likely to have APAP overdose, and had a lower overall 3-week survival compar

88 -hospital settings on mortality, reversal of overdose, and harms, and 2) the need for transport to a

89 rtality, reversal of overdose, recurrence of overdose, and harms.

90 on to the hospital, soon after acetaminophen overdose, and in patients with ALTs in the normal range.

91 estimate overdose amount, time elapsed since overdose, and outcome from patient laboratory values com

92 estimate overdose amount, time elapsed since overdose, and outcome.

93 The leading cause of death in this group was overdose, and primary use of heroin was the only signifi

94 ve indicated potential adverse effects of FA overdoses, and FA protection during processing and stora

95 Patients who had elective surgery, overdoses, and who were expected to stay <24 hrs were ex

96 oRNAs in plasma collected from acetaminophen-overdosed animals are highly expressed in the liver.

97 er tissues and in plasma between control and overdosed animals.

98 disorders, but treatment patterns after the overdose are unknown.

99 Acetaminophen (APAP) overdoses are of major clinical concern.

100 of an enzyme-based novel therapy for cocaine overdose as a successful example in comparison with the

101 istics, hazard ratios of death by accidental overdose associated with prior psychiatric and substance

102 ocytes and attenuated liver injury post-APAP overdose at early time points.

103 2 expression occurs in mice on acetaminophen overdose because of suppression of its key transactivato

104 1 impairs hepatocyte regeneration after APAP overdose; Blockade of HMGB1 enhances liver recovery and

105 Naloxone is effective for reversing opioid overdose, but optimal strategies for out-of-hospital use

106 neration is critical for survival after APAP overdose, but the mechanisms remain unclear.

107 atment with GSH and NAC protect against APAP overdose by dual mechanisms-that is, by enhancing hepati

108 rythropoietin might blunt the benefit of RBV overdosing by enhancing erythrocyte uptake of plasma RBV

109 Acetaminophen (APAP) overdose can cause liver injury in animals and humans by

110 Acetaminophen overdose causes a multitude of interrelated biochemical

111 Acetaminophen (APAP) overdose causes acute liver failure in humans and rodent

112 Acetaminophen (APAP) overdose causes severe, fulminant liver injury.

113 accumulation and higher mortality after APAP overdose compared to ASMase(+/+) littermates.

114 oses were classified as either underdosed or overdosed, consistent with Food and Drug Administration

115 ment method (CRM), CRM using escalation with overdose control, or time-to-event CRM for late-onset to

116 tive Bayesian logistic regression model with overdose control-guided dose escalation.

117 by a Bayesian logistic regression model with overdose control.

118 associations with risk of medication-related overdose death (hazard ratios, 3.02 and 3.07, respective

119 The rate of prescription opioid-related overdose death increased substantially in the United Sta

120 Mortality assessed by drug overdose death rates involving prescription opioids incr

121 02 and 3.07, respectively) than with risk of overdose death related to alcohol or illegal drugs (haza

122 pioids was estimated to be 0.04%.The risk of overdose death was directly related to the maximum presc

123 ere associated with increased risk of opioid overdose death.

124 n former prisoners accounted for 8.3% of the overdose deaths among persons aged 15 to 84 years in Was

125 the past 20 years, leading to high rates of overdose deaths and a dramatic increase in the number of

126 ublic health, resulting in rising numbers of overdose deaths and admissions to emergency departments

127 ribution to heroin users is likely to reduce overdose deaths and is cost-effective, even under marked

128 The rising number of drug overdose deaths and the changing legal status of marijua

129 life-years (QALYs), number and percentage of overdose deaths averted, number of HIV-related deaths av

130 g opioids increase the risk of unintentional overdose deaths but also may increase mortality from car

131 cially given general population increases in overdose deaths from pharmaceutical opioids.

132 The increase in overdose deaths from prescription opioids and heroin in

133 ethanol), and post-mortem analyses of opioid overdose deaths have revealed an inverse correlation bet

134 100 000 person-years [CI, 153 to 181]), and overdose deaths in former prisoners accounted for 8.3% o

135 There are more drug overdose deaths in the Untied States than motor vehicle

136 The majority of overdose deaths in West Virginia in 2006 were associated

137 In the USA, an epidemic of opioid overdose deaths is occurring, many of which are from her

138 In the probabilistic analysis, 6% of overdose deaths were prevented with naloxone distributio

139 neurotoxic and broadly cytotoxic, leading to overdose deaths.

140 ng the impact of underreporting of methadone overdose deaths.

141 surges in opioid-related addiction cases and overdose deaths.

142 hanol may be a contributory factor in heroin overdose deaths.

143 Thus, the outcome of an APAP overdose depends on the size of the overdose and the tim

144 treatment-emergent adverse events including overdose did not differ between treatment groups.

145 TNF-induced apoptosis, indicating that APAP overdose does not cause apoptosis.

146 ne nanosheets were able to detect benzocaine overdose down to a parts-per-billion (ppb) level with an

147 In the midst of the prescription opioid overdose epidemic, electronic surveillance tools that re

148 he authors review the scope of the abuse and overdose epidemic, prescription practices, and the asses

149 ith fully implemented EHRs had fewer heparin overdosing errors (45.7% versus 72.8%; P<0.01) and a hig

150 r the total 78 weeks observed, there were no overdose events in the extended-release naltrexone group

151 tion and delirium consistent with olanzapine overdose following possible accidental intravascular inj

152 ti-HMGB1 neutralizing antibody to treat APAP overdose for 24-48 hours.

153 ne (NAC) is used to treat patients with APAP overdose for up to 48 hours.

154 ous acetylcysteine treatment for paracetamol overdose had circulating biomarkers measured at hospital

155 Serum samples of children with APAP overdose had significant elevation of miR-122-5p, miR-37

156 itous increase in opioid analgesic abuse and overdose has inspired investigation of the dopamine D3 r

157 is change in practice, rates of fatal opioid overdose have increased.

158 Drug overdoses have become the number 1 cause of mortality in

159 Deaths due to prescription opioid overdoses have increased dramatically.

160 In cases of intracameral cefuroxime overdose, hemorrhagic retinal infarction can develop aft

161 ble prognoses being found with acetaminophen overdose, hepatitis A, and ischemia (approximately 60% s

162 n analytical Markov model to simulate opioid overdose, HIV incidence, overdose-related deaths, and HI

163 orrelated with changes in the rate of heroin overdoses (HOD).

164 Women were at increased risk for overdose (HR, 1.38 [CI, 1.12 to 1.69]) and opioid-relate

165 development, and that both GA deficiency and overdose impact on fertility.

166 Here, we found that APAP overdose in mice caused liver damage accompanied by sign

167 Upon experimental APAP overdose in mice, monocyte-derived macrophages (MoMFs) m

168 ministration and dosing for suspected opioid overdose in out-of-hospital settings on mortality, rever

169 d drug, its potential application after APAP overdose in patients should be further explored.

170 ic increases in the rate of fatal accidental overdose in recent years, risk factors for this outcome

171 h death by unintentional prescription opioid overdose in subgroups defined by clinical diagnoses, adj

172 opioids and the risks of misuse, abuse, and overdose in the nonpatient population.

173 ealth interventions that address the risk of overdose in this population in order to reduce premature

174 hiatric medications upon which a patient has overdosed in the intensive care unit, though withdrawal

175 The small number of overdoses in the study cohort is also a limitation.

176 nts who died of unintentional pharmaceutical overdoses in West Virginia in 2006.

177 Concerns about toxicity or overdosing in obese patients with cancer, based on the u

178 meation of the intestine as well as enhancer overdosing in some areas due to non-uniform distribution

179 e, practical emergence treatment for cocaine overdose includes administration of a benzodiazepine ant

180 under conditions of chemical and genetic GA overdose, including mutants in both ecotypes lacking the

181 Using acetaminophen overdose-induced liver injury in the mouse as a model sy

182 APAP overdose induces autophagy, which attenuates APAP-induce

183 APAP overdose induces massive hepatocyte necrosis, necrotic t

184 Acetaminophen (APAP) overdose induces massive hepatocyte necrosis.

185 Unintentional overdose involving opioid analgesics is a leading cause

186 Acetaminophen overdose is a common reason for hospital admission and t

187 Acetaminophen (APAP) overdose is a frequent cause of drug-induced liver injur

188 Opioid overdose is a leading cause of accidental death in the U

189 Acetaminophen (APAP) overdose is a major cause of acute liver failure (ALF).

190 Acetaminophen (APAP) overdose is a major cause of acute liver failure.

191 Acetaminophen (APAP) overdose is a major cause of hepatotoxicity and acute li

192 Nonfatal opioid overdose is an opportunity to identify and treat substan

193 Opioid discontinuation after overdose is associated with lower risk for repeated over

194 ivation of beta-catenin signaling after APAP overdose is associated with timely liver regeneration.

195 Paracetamol overdose is common but patient stratification is subopti

196 Acetaminophen (APAP) overdose is one of the most frequent causes of acute liv

197 Acetaminophen (APAP) overdose is the leading cause of acute liver failure in

198 Acetaminophen overdose is the leading cause of acute liver failure.

199 At the same time, acetaminophen overdose is the most common cause of acute liver failure

200 Acetaminophen (APAP) overdose is the most frequent cause of acute liver failu

201 Acetaminophen (APAP) overdose is the predominant cause of acute liver failure

202 Ca(2+) entry in hepatocytes in acetaminophen overdose is the Transient Receptor Potential Melanostati

203 re not studied and the role of HMGB1 in APAP overdose is unknown, it is possible that neutralization

204 e allosteric cooperativity which may prevent overdose issues, and engendering bias by differentially

205 ytes is a known consequence of acetaminophen overdose, its importance in acetaminophen-induced liver

206 However, APAP overdose leads to massive hepatocyte death.

207 ealed that liver injury due to acetaminophen overdose led to a directional migration of neutrophils t

208 mparing all-cause mortality and drug-related overdose mortality at treatment induction, after in-trea

209 ienced the nation's largest increase in drug overdose mortality rates during 1999-2004.

210 rates (CMRs) for all-cause and drug-related overdose mortality, and mortality rate ratios (MRRs) acc

211 s may be an alternate indicator of trends in overdose mortality.

212 opioid prescribing may be related to risk of overdose mortality.

213 During APAP overdose, neutrophils accumulated into the liver, and bl

214 enic compounds, as occurs with acetaminophen overdose, nitrosamines in cigarette smoke, and reactive

215 Five fatal overdoses occurred (two in the XR-NTX group and three in

216 outcomes of in-hospital postoperative opioid overdose (OD) and identify predictors of postoperative O

217 e that slow signal termination is induced by overdose of a stimulus.

218 Overdose of acetaminophen (APAP) is the leading cause of

219 Overdose of acetaminophen (APAP), the active ingredient

220 These data support the concept that an overdose of APAP results in liver injury that is refract

221 rge number of fatalities have been linked to overdose of fentanyl derivatives.

222 Overdose of gamma-hydroxybutyrate (GHB) frequently cause

223 We conclude that overdose of more than one HSA21 gene contributes to the

224 urine model of acute liver injury induced by overdose of N-acetyl-p-aminophenol (APAP) and defined th

225 detergent composition (liquid or powder) or overdosing of detergent did not significantly influence

226 This is a typical level during ammonia overdosing, often practiced for efficient NOx control.

227 renders prisoners susceptible to relapse and overdose on release.

228 pathy theory in a hyperammonemic patient who overdosed on acetaminophen.

229 c pain is associated with increased risk for overdose, opioid abuse, fractures, myocardial infarction

230 ive and passive immunotherapies for treating overdose or addiction from (+)-METH-like stimulants.

231 Serious outcomes after overdose or nonintentional exposures to medications used

232 d it was cost-saving if it resulted in fewer overdoses or emergency medical service activations.

233 The frequency of fatal overdose over the study period among individuals treated

234 In a cohort of APAP overdose patients (N = 74) with and without established

235 transcriptome changes were observed in human overdose patients and rats receiving toxic doses.

236 fragments can be measured in circulation of overdose patients as mechanistic biomarkers of mitochond

237 analysis of liver samples from acetaminophen-overdose patients demonstrated a positive correlation be

238 caspase-3 were not detectable in plasma from overdose patients or mice, but were elevated after TNF-i

239 RNAs were quantified in age- and sex-matched overdose patients with (N = 27) and without (N = 27) org

240 Overdose patients with no or minimal hepatic injury who

241 the plasma or serum of acetaminophen (APAP) overdose patients.

242 fragments were measured in plasma from APAP-overdose patients.

243 tocols using BZ and NFX may be significantly overdosing patients, perhaps contributing to the adverse

244 oubled over the study period from 0.6 to 1.1 overdoses per 1000 cases.

245 c disorders with risk of death by accidental overdose persisted after additional adjustment for subst

246 changes in the rates of Prescription Opiate Overdoses (POD) are correlated with changes in the rate

247 uggest the importance of risk assessment and overdose prevention for vulnerable clinical subpopulatio

248 tension, cardiomegaly, increased creatinine, overdose (primarily calcineurin inhibitor toxicity), acn

249 The ongoing epidemics of opioid overdose raises an urgent need for effective antiaddicti

250 ceiving 1 to 20 mg/d of opioids (0.2% annual overdose rate), patients receiving 50 to 99 mg/d had a 3

251 risk (95% CI, 1.5 to 9.5) and a 0.7% annual overdose rate.

252 ose risk (CI, 4.0 to 19.7) and a 1.8% annual overdose rate.

253 Opiate abuse and overdose reached epidemic levels in the United States.

254 Main outcomes were mortality, reversal of overdose, recurrence of overdose, and harms.

255 to simulate opioid overdose, HIV incidence, overdose-related deaths, and HIV-related deaths in peopl

256 ) liver failure, such as after acetaminophen overdose, remain at highest risk.

257 m or bleeding associated with underdosing or overdosing, respectively.

258 Acetaminophen (APAP) overdose results in acute liver failure and has limited

259 ing 50 to 99 mg/d had a 3.7-fold increase in overdose risk (95% CI, 1.5 to 9.5) and a 0.7% annual ove

260 100 mg/d or more had an 8.9-fold increase in overdose risk (CI, 4.0 to 19.7) and a 1.8% annual overdo

261 arly scheduled doses was not associated with overdose risk after adjustment.

262 rtional hazards models were used to estimate overdose risk as a function of average daily opioid dose

263 The extent to which overdose risks are elevated among patients receiving med

264 scribe a series of distinct "retrotransposon overdose" (RO) lineages in which the number of Ty1 eleme

265 Secondary outcomes included time to repeated overdose stratified by daily dosage as a time-varying co

266 (natural) diseases, and 44 (19%) were due to overdoses, suicides, or unknown causes.

267 various strategies in a mouse model of APAP overdose, the authors demonstrate that platelets partici

268 ly allocated patients with acute paracetamol overdose to either the standard intravenous acetylcystei

269 ctable plasma concentration exposing them to overdose, toxicity, underdosing, and treatment failure.

270 esponse relationship or effects of potential overdose treatment strategies on GHB-induced respiratory

271 ical evidence of clinical potential for drug overdose treatment without a question mark on the timing

272 ng the efficacy of the enzyme in the cocaine overdose treatment.

273 f melanoma, and when accounting for putative overdosing, trended toward an increase in the survival b

274 response to rising rates of opioid abuse and overdose, U.S. states enacted laws to restrict the presc

275 finition, DLT rate, patient-dose allocation, overdose, underdose, sample size, and trial duration wer

276 The literature on insulin overdose, usually from suicide attempts, can help guide

277 years, the cumulative incidence of repeated overdose was 17% (95% CI, 14% to 20%) for patients recei

278 Death by accidental overdose was determined using National Death Index recor

279 Health Administration, death from accidental overdose was found to be associated with psychiatric and

280 Nonfatal opioid overdose was identified using International Classificati

281 In a "worst-case scenario" where overdose was rarely witnessed and naloxone was rarely us

282 Overdose was the leading cause of death (167 per 100 000

283 After dose adjustment, NOAC overdosing was associated with increased all-cause morta

284 red acetylcysteine treatment for paracetamol overdose were recruited (985 in the MAPP cohort; 202 in

285 ical or historical evidence of acetaminophen overdose were stratified by site and coma grade and assi

286 ty and liver injury at early times post-APAP overdose were unaffected by syndecan-1, suggesting that

287 51 opioid-related overdoses were identified, including 6 deaths.

288 umber of deaths were one and zero, non-fatal overdoses were one and two, admissions to hospital were

289 Primary outcomes--nonfatal and fatal overdoses--were identified through diagnostic codes from

290 ALF was induced in mice by acetaminophen overdose, which is also a leading cause of liver failure

291 awareness with recall, as well as anesthetic overdose, which may be associated with adverse events.

292 prescribed opioids are at increased risk for overdose, which underscores the need for close supervisi

293 n for dose reduction, 43.0% were potentially overdosed, which was associated with a higher risk of ma

294 Nontransport after reversal of overdose with naloxone seems to be associated with a low

295 nsport versus nontransport after reversal of overdose with naloxone.

296 to a health care facility after reversal of overdose with naloxone.

297 tial for biomarkers to stratify patients who overdose with paracetamol.

298 The numerous opportunities for overdosing with antipyretics have been emphasized by the

299 ity, including deaths from causes other than overdose, with a modest absolute risk difference.

300 ntramuscular naloxone for reversal of opioid overdose, with no difference in adverse events.